Since pattern visual evoked potential (VEP) mea when a Sinemet 250 bolster was administered. These results are reported in the section "effect of acute dopamine precursor administration". In all the Parkinson's disease patients, the Parkinsonian symptoms were rated hourly on the scale of the "Clinical Center for Research in Parkinson's and Allied Diseases"20 with the purpose of further elucidating the relationship of VEP latency delays and the clinical picture of Parkinsonism. Tremor (scale 0-4 for each limb), rigidity (scale 0-4 for each limb), bradykinesia (scale 0-4) and gait disturbance (scale 0-4) were reported for each patient before and after 5-7 days treatment with Sinemet. In two stage II and three stage III patients, VEP studies were performed prior to the drug wash-out period, when the patients were experiencing transient oscillations of their clinical status. These transient disturbances were of the "end-start dose failure" or "wearing-off' kind.20 VEPs were studied during the wearing-off akinesia state, and when the patients had overcome the akinetic period, as assessed by the hourly rating scale. Parkinsonian Syndromes. Six other patients, considered outside the group of "idiopathic Parkinsonism" were similarly studied. Two Parkinsonian syndrome subjects (one male 67 years old and one female 72 years old) were affected by arteriosclerotic pseudo-Parkinsonism. Two male patients, ages 59 and 67, were classified as having progressive supranuclear palsy; in a 59-year-old female a diagnosis of multiple system atrophy, probably of the olivopontocerebellar atrophy (OPC) type, was made. The last patient, a 56-year-old female, was affected by autosomal dominant familial Parkinsonism; she presented with a predominant akinetic-rigid symptomatology which responded to Sinemet treatment.
Haloperidol study. In eight patients, ages 24-36, each with an acute paranoid state, VEPs to 1, 2 and 4 cycles per degree (cpd) grating stimulation were recorded before and after administration of 6 mg IV haloperidol (in three different doses). The VEP latencies and amplitudes were compared with data of the 28 control subjects of the same age range (31 6 + 6-8 years). In four of these patients, VEPs were also recorded using 0 5 cpd grating.
(c) Stimulus and recording apparatus VEPs were recorded in an electrically shielded dark room of 2 x 4 m. The pattern generator, amplifiers and averaging system were part of an Amplaid MK 6 Evoked Potential recording unit. Vertical gratings with a square wave luminance profile were presented on the screen of the Amplaid monitor. The monitor was placed at 57 cm from the observer's eye. The border of the screen was covered with an opaque mask of 6 cm width. The central stimulating part of the screen subtended 180 of the observer's visual angle. The mean luminance was 65 cd/m2. The contrast, defined as the ratio of the difference of maximum and minimum luminances of adjacent bands over their summed luminances, was 50%. We calibrated the minimum and the maximum luminances by means of a Centronic Photodiode photometer for all the spatial frequencies tested. The patients were requested to fixate a central horizontal 0-5 x 0-2 cm bar. Linear and multiple regressions, t tests and one-way Analyses of Variance (ANOVA) were performed using VEP data from the three spatial frequency patterns. VEP data, both pre-and post-dopamine precursor treatment, were compared with clinical scores (both initial and post-treatment), age, and disease stage and duration. The effect of haloperidol was similarly evaluated. Multiple correlations were also performed on VEP data of the 10 patients undergoing acute dopamine precursor administration. Any significant correlation between these data would indicate that VEP changes after a single dose of Sinemet could be used to predict the results of dopamine precursor therapy in these patients.
Results (a) Controls
The mean latency and amplitude measurements of VEPs obtained with stimuli of 1, 2 and 4 cpd to each eye, and the mean interocular latency differences in the two control groups (ages 20-48 and 52-75) are listed in table 1. The major positive wave latency in individual control subjects at each spatial frequency did not vary by more than 4 ms when recorded on the same day. Where testing sessions were separated by weeks, the broadest variations for the latency of the major positive peak was + 9 ms. The mean of latency variability was 3 84 + 2 58 ms. The 99 5% confidence limit of interocular latency differences was 9 ms, inde- 4-8 + 21 fortremor,3-6 + 15 forrigidity, 19 + 0-7 for bradykinesia and 1-7 + 0 9 for gait. The chronic levodopa treatment reduced the clinical scores to 3-8 + 2 8 for the tremor, 2-8 + 1-2 for rigidity, 1-6 0-9 for bradykinesia and 1-6 + 0-8 for gait. (e) Haloperidol study In all eight patients, the administration of IV haloperidol (4 mg) induced an increment of VEP latencies which was most evident when 2 and 4 cpd, rather than I cpd stimuli, were used. Figure 5 highlights the relationship between spatial frequency and VEP latency increment after haloperidol administration. After haloperidol administration, the mean VEP latencies were 106 4 + 4 7 ms (I cpd), 114 0 + 7 1 ms (2 cpd) and 129 7 + 7-1 (4 cpd). Amplitudes posttreatment were 6 8 + 1 1 pV (1 cpd); 64 + 1 1 (2 cpd) and 3 1 + 0 7 (4 cpd). The mean values of VEPs to 0 5 cpd stimuli was 103 3 + 3-1 ms for latency and 6-6 + I 1 jiV for amplitude. The ANOVA of pre-vs post-treatment did not show significant variations in amplitude, while the levels of significance for latency were 0 02 for I cpd and 0 001 for both 2 and 4 cpd stimuli. The ANOVA with age-matched normal controls showed no differences of latencies and amplitudes when the data collected in these patients before haloperidol administration were compared with control data. When control group data were compared with VEP latencies obtained after haloperidol administration, a significance level of 0 001 was reported for 4 cpd. Figure 6 is a scattergram of VEP latencies to the different spatial frequencies of stimulation, prior and after haloperidol administration. fig 1) . The VEP latency increases as a function of increasing spatial frequency23-25 in normal subjects, and our results show that this latency increase is enhanced in Parkinson's disease and also when dopamine blockers are administered.
We show, moreover, that VEP delays are reduced or suppressed by dopamine precursor therapy and that the dopamine dependent correction of VEP delays is more evident when 4 or 2 cpd stimuli are used rather than 1 cpd (table 2, fig 1) . 
